Everwell Health Expands Portfolio with Acquisition of American River Nutrition

In a significant strategic move, Everwell Health has announced the acquisition of American River Nutrition (ARN), which is based in Hadley, Massachusetts. This marks the company's third major strategic transaction in just three months, showcasing its commitment to enhancing its portfolio of health-driven functional ingredients. The acquisition, announced on May 5, 2025, focuses on integrating ARN's proprietary extract-based ingredients and manufacturing technologies into Everwell Health's offerings.

Founded by Dr. Barrie Tan in 1998, American River Nutrition has focused on the scientific exploration of the health benefits of the Bixa orellana plant, commonly referred to as annatto. The company is known for its unique ingredients, such as DeltaGold® and GG-Gold®, which have both been scientifically validated for their health benefits. DeltaGold® serves as a tocopherol-free source of tocotrienols, noted for their potent antioxidant properties, while GG-Gold® is a crucial nutrient that helps in protein synthesis and production of essential compounds like testosterone and CoQ10.

Everwell Health plans to utilize ARN's ingredients to extend its reach in vital health sectors including metabolic, cardiovascular, and men's health. Steve Rosenman, the CEO of Everwell Health, expressed his enthusiasm about this acquisition, stating that it aligns perfectly with their commitment to providing scientifically backed functional ingredients that empower consumers to lead healthier lives. The addition of ARN's specialized manufacturing capabilities will significantly enhance their production of nature-based bioactive ingredients.

ARN’s Hadley facility will not only continue operations but will also become Everwell Health's main Innovation Center, where further investments will be made to ensure the highest quality and effective production processes. The facility utilizes a cutting-edge manufacturing process that isolates and concentrates key bioactive compounds without harsh chemicals, ensuring that the end products are pure and beneficial to health.

While the transaction is largely positive, it’s worth mentioning that the ingredient DuoQuinol is not included in this acquisition and will remain under the ownership of Designs for Health, the previous owner of ARN. Despite this, ARN will continue to operate under its current name as part of Everwell Health until the end of 2025, after which it will be fully integrated into the broader Everwell Health brand.

Looking ahead, Everwell Health remains dedicated to innovating new products and expanding its ingredient lineup, aimed at enhancing health and wellness for consumers. This acquisition represents not just a growth opportunity for Everwell Health but also underscores its commitment to supporting proactive health management for individuals at all stages of life. With a portfolio built on scientific research and clinical efficacy, Everwell Health and ARN stand poised to make a significant impact in the dietary supplement and functional foods market.

As Everwell Health continues to grow, customers and supply chain partners of ARN will reap the benefits of enhanced access to cutting-edge ingredients and expertise, reinforcing the mission of both companies to help individuals look, feel, and perform their best. With this transaction, Everwell Health not only fortifies its position in the market but also illustrates the power of scientific innovation in the health and dietary supplement industry.